SCHEMBL6080607

SCHEMBL6080607

Cc1cc(NC(=O)NC2CCN(CCCc3ccccc3)C2)c2ccccc2n1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CXCR3 P49682 2/20 0.55
UTS2R Q9UKP6 2/20 0.51
SIGMAR1 Q99720 2/20 0.51
ADRA2A P08913 1/20 0.51
DRD2 P14416 1/20 0.51
SLC6A2 P23975 1/20 0.51
HTR2A P28223 1/20 0.51
HTR2C P28335 1/20 0.51
SLC6A4 P31645 1/20 0.51
TMEM97 Q5BJF2 1/20 0.51
DRD4 P21917 4/20 0.49
HTT P42858 2/20 0.49
GALR3 O60755 1/20 0.49
RAB9A P51151 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
KDM4E B2RXH2 1/20 0.46
TSHR P16473 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6080158 0.95 CXCR3 (0.54) CXCR3UTS2RSIGMAR1ADRA2ADRD2
SCHEMBL6079692 0.89 SIGMAR1 (0.59) UTS2RSIGMAR1ADRA2ADRD2SLC6A2
SCHEMBL6078746 0.89 SIGMAR1 (0.59) UTS2RSIGMAR1ADRA2ADRD2SLC6A2
SCHEMBL6078750 0.89 SIGMAR1 (0.59) UTS2RSIGMAR1ADRA2ADRD2SLC6A2
SCHEMBL6200289 0.88 UTS2R (0.61) CXCR3UTS2RSIGMAR1ADRA2ADRD2
SCHEMBL6078927 0.86 UTS2R (0.48) UTS2RSIGMAR1ADRA2ADRD2SLC6A2
SCHEMBL6079575 0.86 UTS2R (0.48) UTS2RSIGMAR1ADRA2ADRD2SLC6A2
SCHEMBL6078919 0.86 UTS2R (0.48) UTS2RSIGMAR1ADRA2ADRD2SLC6A2
SCHEMBL6197953 0.85 UTS2R (0.65) UTS2RSIGMAR1ADRA2ADRD2SLC6A2
SCHEMBL6194472 0.85 UTS2R (0.60) CXCR3UTS2RSIGMAR1ADRA2ADRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060094716-A1 1-Pyridin-4-yl-urea derivatives ACTELION PHARMACEUTICALS LTD (CH) 2006-05-04 US claimed
EP-1554249-A2 1-PYRIDIN-4-YL-UREA DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2005-07-20 EP claimed
WO-2004026836-A2 1-PYRIDIN-4-YL-UREA DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2004-04-01 WO claimed
US-20060094716-A1 1-Pyridin-4-yl-urea derivatives ACTELION PHARMACEUTICALS LTD (CH) 2006-05-04 US disclosed
EP-1554249-A2 1-PYRIDIN-4-YL-UREA DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2005-07-20 EP disclosed
WO-2004026836-A2 1-PYRIDIN-4-YL-UREA DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2004-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094716-A1 1-Pyridin-4-yl-urea derivatives P2RY4, P2RX4, REN CXCR3 3447/4885UTS2R 6/4885SIGMAR1 162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.